Ed two models. Model 1 was constructed using variables with P
Ption were detected. All analyses were performed with Stata version 10.1 (StataCorp, College Station, TX, USA). A two-sided P-value
Tion-inducing activities of ESR1 [1,2]. Unraveling the precise role of DC-SCRIPT in the complex genomic and non-genomic interplay between ESR1, ESR2, and their isoforms [21-23] might turn out to be rewarding for elucidating the `yin-yang' role of these factors in breast cancer. As DC-SCRIPT can inhibit ERa and PR activity, a second aim of the study was to address whether DCSCRIPT affects the respo
Noma in situ; DC-SCRIPT, dendritic cell-specific transcript gene; ERBB2+, HER2neu-positive; ESR, estrogen receptor gene; IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular carcinoma; PGR, progesterone receptor gene; pT1, small tumor without lymphatic/vascular invasion.(Spearman's rho = 0.87; P
IcsResultsAssociations of DC-SCRIPT with clinicopathological factors and histological and intrinsic breast cancer subtypesThe relationship between DC-SCRIPT and patient and tumor characteristics was investigated with the use of non-parametric methods (Spearman rank correlations for continuous variables and Wilcoxon rank-sum for dichotomized or Kruskal-Wallis test for ordered variables). To reduce
Ith DFS, MFS, OS, and PFS, respectively. In multivariable analysis, Cox proportional hazards models for DFS, MFS, OS, and PFS were applied to test DCSCRIPT levels added to models with traditional factors. The proportional hazards assumptions were checked with Schoenfeld residuals. The analyses were stratified if necessary. The models for DFS, MFS, and OS for LNN patients who had not received adjuv
Ator of nuclear receptors, we explored its prognostic value in relation to estrogen-receptor-a (ESR1) and -b (ESR2) and evaluated its predictive value for response to tamoxifen treatment. Methods: DC-SCRIPT mRNA levels were measured by real-time PCR in 1,505 primary invasive breast cancers and associated with outcome (disease-free survival (DFS), metastasis-free survival (MFS) and overall survival
And the US Army Medical Research Acquisition Activity W8IWXH-04-1-0474 to DSC.Sieuwerts et al. Breast Cancer Research 2010, 12:R103 http://breast-cancer-research.com/content/12/6/RRESEARCH ARTICLEOpen AccessClinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation studyAnieta M Sieuwerts1, Marleen Ansems2, Maxime P Look1, P